Summary#
This law reauthorizes and updates many federal programs that prevent and treat substance use disorders, support recovery, and fund related public-health activities through 2030. The main changes are new or extended funding authorizations, program expansions (for example fetal alcohol spectrum disorder services and youth prevention), new reporting and guidance requirements, and steps to protect the 9‑8‑8 suicide lifeline from cybersecurity problems. The broad goal is to continue and broaden federal support for prevention, treatment, recovery, research, and related workforce and technology activities after earlier authorizations expired.
Key changes:
- Funding authorizations: The law sets new authorization levels for many programs for fiscal years 2026–2030 (examples below).
- FASD programs: Creates a new part for fetal alcohol spectrum disorder (FASD) prevention, services, research, and grants, and authorizes $12.5 million per year for 2026–2030.
- Prevention and overdose response: Expands the scope of overdose monitoring and grants (including allowing some innovative approaches such as wastewater surveillance, with privacy caveats) and raises an annual authorization to roughly $505.6 million for those activities.
- 9‑8‑8 cybersecurity: Requires steps to protect the National Suicide Prevention Lifeline from cybersecurity incidents and new reporting duties for network administrators and crisis centers.
- Workforce and treatment support: Raises or reauthorizes funding for programs such as loan repayment for substance use disorder treatment workforce ($40 million/year) and grants for recovery and workforce support (various amounts).
- Other actions: Requires FDA/FDA‑related reporting on opioid analgesics and on review of scheduling for products that combine buprenorphine and naloxone; issues guidance on at‑home drug disposal; allows grant purchases of fentanyl/xylazine test strips consistent with law; and updates training and certification references for prescribers.
What it means for you#
-
People with substance use disorder and their families
- More federal grant programs and resources may be available for prevention, treatment, recovery housing, peer support, and services tailored to pregnant and postpartum women.
- Grants may fund local programs for youth prevention and recovery and for family education about fentanyl and other synthetic opioids.
-
Pregnant and postpartum women
- Residential treatment programs and related outreach may receive renewed funding and applicants may describe targeting outreach to women disproportionately affected by maternal substance use.
-
People affected by fetal alcohol spectrum disorder (FASD)
- New federal programs will support prevention, diagnosis, culturally appropriate interventions, training, and a clearinghouse of best practices. States, Tribes, nonprofits, and researchers can apply for grants.
-
First responders, crisis centers, and 9‑8‑8 operators
- First responder training grants are broadened beyond “opioid” to include other drugs and overdoses, and funding authorizations are increased.
- 9‑8‑8 network administrators and participating crisis centers must report cybersecurity vulnerabilities and incidents to the Assistant Secretary (in a way that protects personal privacy). The Comptroller General must study 9‑8‑8 cybersecurity risks.
-
State and Tribal governments
- More grant programs and extended eligibility windows. States keep the ability to choose vendors and interoperability connections for prescription drug monitoring programs (PDMPs), provided they align with national open standards.
- Grants may pay for fentanyl or xylazine test strips where legal under state and federal law.
-
Health care providers and pharmacies
- Updates to training and approved organizations for required prescriber training. Changes to rules on delivering certain controlled substances from pharmacies to prescribing practitioners for specific treatment uses.
- FDA is asked to report on how it assesses approved opioid analgesics and to consider support for nonaddictive pain treatments.
-
Researchers and public‑health agencies
- New reporting and evaluation requirements, grants for innovative monitoring (including wastewater surveillance if lawful and “actionable”), and a roundtable on electronic health record use in mental health and substance use care.
-
Grant applicants and SAMHSA applicants
- The Secretary must convene public meetings and work to improve access to information about SAMHSA funding opportunities and to implement certain website improvements.
Expenses#
No official cost estimate or CBO score is included in the law text provided. The law authorizes, but does not itself appropriate, funding for many programs. Major authorizations shown in the statute include:
- Prevention and monitoring grants (section amended): $505,579,000 for each of fiscal years 2026 through 2030.
- FASD prevention and services: $12,500,000 for each of fiscal years 2026 through 2030.
- National Child Traumatic Stress Initiative (NCTSI) amounts: $98,887,000 for fiscal years 2026–2028 and $100,000,000 for fiscal years 2029–2030.
- First responder training grants: $57,000,000 for each of fiscal years 2026 through 2030.
- Loan repayment for substance use disorder treatment workforce: $40,000,000 for each of fiscal years 2026 through 2030.
- Residential treatment for pregnant/postpartum women: $38,931,000 for each of fiscal years 2026 through 2030.
- Building communities of recovery: $17,000,000 for each of fiscal years 2026 through 2030.
- Peer support technical assistance center (regional centers): $2,000,000 for each of fiscal years 2026 through 2030 (for the center funding line listed).
- Youth prevention and recovery grants: $10M (FY2026), $12M (FY2027), $13M (FY2028), $14M (FY2029), $15M (FY2030).
- CAREER Act grants: $12,000,000 for each of fiscal years 2026 through 2030 (as amended).
Additional programs in the law are reauthorized or extended without a new dollar figure shown in the text supplied. Authorization means Congress allows funds to be appropriated; actual spending requires future appropriations.
No publicly available information in the supplied text gives a total expected cost, a budget offset, or a formal fiscal estimate.
Proponents' View#
The bill appears intended to:
- Keep and expand federal support for prevention, treatment, and recovery services through 2030 so programs do not lapse.
- Strengthen services for specific populations (pregnant and postpartum women, youth, people with FASD, people experiencing trauma).
- Improve overdose detection and response by modernizing surveillance and supporting innovative detection methods where lawful and actionable.
- Protect critical crisis services (9‑8‑8) from cybersecurity threats and improve reporting and oversight of such threats.
- Support workforce development and retention (loan repayment, workforce grants, CAREER Act), and improve training for prescribers and peer specialists.
- Encourage the development and availability of opioid overdose reversal drugs and nonaddictive pain treatments by requiring FDA-related reporting and inclusive grant language.
These goals are stated in program descriptions, funding authorizations, and reporting requirements throughout the law text.
Opponents' View#
The law’s text suggests several possible concerns or trade-offs:
- Authorizations do not equal appropriations. The statute authorizes funding levels but does not guarantee Congress will appropriate the money. It is unclear how much of the authorized funding will be provided in practice.
- Administrative and reporting burden. The law adds multiple new reporting, evaluation, and oversight requirements for HHS, grantees, crisis centers, and network administrators. This may require additional administrative work and resources at federal, state, and local levels.
- Privacy and legal issues for surveillance methods. The law allows innovative monitoring (for example wastewater surveillance) only “if proven to support actionable prevention strategies” and “consistent with applicable Federal and State privacy laws.” The statute does not define how privacy concerns will be resolved in practice.
- Cybersecurity reporting overlap. The law adds specific cybersecurity reporting duties for 9‑8‑8 program participants while also saying these requirements “supplement, and not supplant” other federal laws; it is unclear how reporting will be coordinated to avoid duplication.
- Unclear implementation details. Some actions (for example the FDA’s plan to assess opioid analgesics and the HHS review of scheduling for buprenorphine‑naloxone combinations) are directed but the law does not set detailed timelines or resource levels for follow-through beyond deadlines for some reports. This can make the real-world timing and impact uncertain.
What is unclear
- How much of the authorized funding will be appropriated in future budgets.
- How specific privacy safeguards will be applied to novel surveillance methods.
- How new cybersecurity reporting requirements will interact with existing federal and state incident‑reporting laws and obligations.